Skip to main content
. 2020 Dec 9;100(19):5946. doi: 10.2340/00015555-3700

Fig. 5.

Fig. 5

Change in (A) Dermatology Life Quality Index (DLQI) total scores and (B) the proportion of patients achieving DLQI (0, 1) for patients with psoriasis treated with ixekizumab (IXE) or ustekinumab (UST) for 52 weeks. DLQI (0, 1) results previously reported for weeks 0–24 (12). **p < 0.01, ***p < 0.001, both vs UST by Wilcoxon rank sum test. mBOCF: modified baseline-observation carried forward; NRI: non-responder imputation.